Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's PMDA looks to the future as it balances access and safety

This article was originally published in Scrip

Executive Summary

Since it was set up in April 2004, bringing together drug and medical device regulatory functions then split between various government bodies, the PMDA has not always elicited the kindest of comments from applicants. Frustrations have sometimes been expressed at review times, procedures and difficulties finding slots for consultations. But things have improved markedly over the last few years and the tone of comments one now hears from industry has become much more positive.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts